Rhonda G. Kost, Edgar L. Hill, Michael Tigges
Dec 9, 1993
Citations
4
Influential Citations
151
Citations
Quality indicators
Journal
The New England journal of medicine
Abstract
Acyclovir has been widely used over the past decade as an effective and safe drug for the treatment of infections with herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2)1. Resistance to acyclovir was initially noted only in studies of HSV infection in vitro and in animal models,2–4 then it was found in immunocompromised patients, and it has now become a well-documented clinical challenge to the care of patients infected with the human immunodeficiency virus (HIV)4–12. Acyclovir resistance has not been a problem to date in the treatment of immunocompetent people with HSV infection. Although . . .